SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
about
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growthUse of proteins as biomarkers and their role in carcinogenesis.ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.Stem and progenitor cell alterations in myelodysplastic syndromes.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.The biomarkers of leukemia stem cells in acute myeloid leukemia.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.Targeting Leukemia Stem Cells in the Bone Marrow Niche.DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells.
P2860
Q33588245-CC93ACFA-6ECB-406E-81B6-C8536881F6B0Q34784895-E2752437-CA75-438D-AEF7-CFB1F1F8FC66Q36618978-2ED993B7-4821-4CA4-A703-312B7285406BQ37422094-0E21F29B-4CC3-47A9-934B-285B4DCC734FQ38737657-3317F584-EC7C-40CF-A08F-982F4939BFA1Q38761791-427FFB6E-882B-4712-B446-528689B2CE4EQ38767908-2945C563-72A0-4542-9435-2B7967DFF6E2Q39265778-118DC24F-11FE-42F6-B18E-CB67A21F1EC1Q39411920-C07C6CE6-73EA-47B6-99BB-06D51B305EC2Q48158203-A29A35D3-9188-4694-853B-EBA07BF48705Q50581082-BD879DC4-A4E7-405D-A252-C9EC53503EC1Q51016220-05EA8647-BD00-4D63-BC95-BD91735C96C1Q52375473-2AE3BA08-D948-499D-8491-8FC071D04D7EQ52633239-22DFC7DE-23A1-442C-B368-F2DE22C861CEQ53629318-AAE9FA76-C5EC-4B34-B021-715D68E47C41
P2860
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@ast
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@en
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@nl
type
label
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@ast
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@en
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@nl
prefLabel
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@ast
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@en
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@nl
P2093
P2860
P50
P356
P1476
SL-401 and SL-501, targeted th ...... ase chronic myeloid leukaemia.
@en
P2093
Borys Korchin
Chris Brooks
Eric K Rowinsky
Juliana Benito
Olga Frolova
Rui-Yu Wang
P2860
P304
P356
10.1111/BJH.12978
P407
P577
2014-06-19T00:00:00Z